Description: Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of immunotoxins called engineered toxin bodies for the treatment of cancer and other serious diseases. It develops MT-3724, a lead drug candidate that is in a Phase 1 clinical trial in heavily pre-treated non-Hodgkin's lymphoma patients; MT-4019, a preclinical drug candidate targeting CD38; and evofosfamide, an investigational hypoxia-activated prodrug of a bis-alkylating agent that is preferentially activated under severe hypoxic tumor conditions, a feature of many solid tumors. The company is headquartered in Austin, Texas.
Home Page: www.mtem.com
MTEM Technical Analysis
9301 Amberglen Boulevard
Austin,
TX
78729
United States
Phone:
512 869 1555
Officers
| Name | Title |
|---|---|
| Dr. Eric E. Poma Ph.D. | CEO, Chief Scientific Officer & Director |
| Ms. Jason S Kim | Pres & COO |
| Dr. Roger J. Waltzman M.B.A., M.D. | Chief Medical Officer |
| Mr. Sean McLennan | Sr. VP of Fin., Controller, Interim Principal Accounting Officer, Interim CFO & Treasurer |
| Ms. Megan C. Filoon | Gen. Counsel & Sec. |
| Mr. Kurt Elster | Exec. VP of Corp. Devel. |
| Dr. Jack Higgins Ph.D. | Exec. VP of Operations & Head of Manufacturing |
| Dr. Erin Willert Ph.D. | Exec. VP of R&D |
| Dr. Jen-Sing Liu Ph.D. | Exec. VP of Manufacturing |
| Mr. Michael Dowd | Sr. VP of Project & Alliance Management |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 5.9989 |
| Price-to-Sales TTM: | 0.7223 |
| IPO Date: | 2005-02-04 |
| Fiscal Year End: | December |
| Full Time Employees: | 224 |